

Ophthalmic Drugs Market - Forecasts from 2020 to 2025

<https://marketpublishers.com/r/O168F48726F4EN.html>

Date: April 2020

Pages: 120

Price: US\$ 3,160.00 (Single User License)

ID: O168F48726F4EN

Abstracts

The ophthalmic drugs market is projected to grow at a CAGR of 6.32% to reach US\$47.428 billion by 2025, from US\$32.267 billion in 2019. Rising cases of serious eye diseases are pushing the pharmaceutical companies to launch better and enhanced drugs to cater to the increasing demand among the patients for better and more effective treatment.

According to the World Health Organisation (WHO) Statistics presented in the Blindness and Vision Impairment 2019, about 2.2 billion people are suffering from vision impairment or blindness. Out of the 2.2 billion, at least 1 billion people suffer from a vision impairment that could be prevented or are not addressed. The majority of the people are over the age of 50 years. Moreover, there is a rise in the prevalence of eye diseases such as Wet AMD, which is a chronic disease that is caused due to the excess of VEGF, a protein that is responsible for promoting the growth of abnormal blood vessels under the macula (which is an area of the retina that aids in the sharp and clear vision). So, when the fluid leaks out of these blood vessels and hinders the vision, then there is a requirement of drugs that inhibit the VEGF and suppress the growth of abnormal blood vessels. In addition, the rise in diseases such as glaucoma in the rising geriatric population is also a factor that is leading to increased demand for ophthalmic products and augmenting the market growth.

The presence of stringent packaging restrictions, which the market players have to strictly and must adhere to, in order to avoid the imposition of penalties

There are stringent measures with regards to the packaging of the ophthalmic products in terms of colored caps and drug labeling. The yellow and blue-capped ophthalmic drugs are to be labeled as B blockers, red-capped ophthalmic drugs are to be labeled

as Mydriatics and cycloplegics. There are also green-capped ophthalmic drugs that are to be labeled as Miotics, orange capped are labeled as Carbonic anhydrase inhibitors, brown capped are to be labeled as Anti-infective agents and the gray and pink capped products are to be labeled as Non-Steroidal Anti-Inflammatory Drugs and Steroids respectively.

Major Market Developments

The launch of better-equipped and new and enhanced varieties of ophthalmic drugs in order to cater to the increases cases of serious diseases and rare diseases by existing and new players in different markets is expected to propel the growth of this market in the forecast period.

Some of the examples of the product offerings are as follows:

Recently in January 2020, Horizon, one of the leading pharmaceutical companies dealing in the provision, announced that their new drug TEPEZZA (teprotumumab-trbw), which has been developed for the treatment of Thyroid Eye Disease (TED) has been approved by the FDA. This disease is a progressive, rare and autoimmune disease, which can be vision threatening and is associated with proptosis (eye bulging) and diplopia (double vision), blurred vision, and pain among other problems. This is a type of a fully human monoclonal antibody (mAb) and a targeted inhibitor of

the insulin-like growth factor-1 receptor (IGF-1R), that needs to be provided to the patients once in three weeks, for a total of eight infusions.

In October 2019, Novartis, one of the leading companies dealing in the provision of healthcare solutions and drug deve

lopment, announced that they have received an FDA approval for their ophthalmology drug “Beovu” (brolucizumab) injection. This drug has been developed for the purpose of

treati
ng
wet
age-
relat
ed m
acul
ar de
gene
ratio
n (A
MD).
This
drug,
whic
h
has
been
appr
oved
by
the
FDA
is
such
an a
nti-V
EGF
drug
that
is
able
to
offer
both
great
er
fluid
resol

ution
in co
mpar
ison
to afl
iberc
ept
and
the a
bility
to m
ainta
in eli
gible
patie
nts s
ufferi
ng
from
the d
osin
g int
erval
of
three
mont
hs,
with
maki
ng a
com
prom
ise
of
the e
ffica
cy.

In July 2019, Novartis, one of the leading companies dealing in the

provision of healthcare solutions and drug development announced that their drug “Lucentis” (ranibizumab) has been recommended for approval for the treatment of preterm infants with retinopathy of prematurity (ROP) by the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA). ROP is a rare eye disease but it is one of the leading causes of childhood blindness.

The North American and European region to hold a considerable share over the forecast period

The North American region is estimated to hold a considerable share over the forecast period, which is attributable to the fact that the pharmaceutical industry is flourishing facilitated by the influx of investments. Moreover, with research and development activities are being carried out to improve and enhance the ophthalmic drugs and provide a boost to the market growth.

OTC drugs are being made easily available by market players, which is going to contribute to the market share of OTC’s over the forecast period

Some of the major market players are involved in the provision of ophthalmic drugs that can be purchased over the counter. Bausch & Lomb and Sentiss provide a range of products such as drops and ointments for eye problems, that is able to provide temporary relief for occasional and frequent users alike.

Solution and suspension is expected to hold a significant share and show considerable growth over the forecast period.

Solution and Suspension ophthalmic products are most commonly used in eye care, as they do not hamper the vision, can be instilled easily and are less likely to cause any complications.

Segmentation:

By Indication

Dry Eye

Glaucoma

Infection/Inflammation/Allergies

Retinal Problems

Others

By Product type

OTC Drug

Prescription Drug

By Drug Form

Liquid

Semi-Solid

Solid

By Drug Class

Anti-Inflammatory

Anesthetic

Anti-Allergy

Others

By Delivery Method

Local

Topical

Intravitreal

Sub-conjunctival

Others

Systematic

By Distribution Channel

Online

Offline

By Geography

North America

USA

Canada

Mexico

South America

Brazil

Argentina

Others

Europe

UK

Germany

France

Spain

Others

Middle East and Africa

Saudi Arabia

UAE

Israel

Others

Asia Pacific

Japan

China

India

Others

Contents

1. INTRODUCTION

- 1.1. Market Definition
- 1.2. Market Segmentation

2. RESEARCH METHODOLOGY

- 2.1. Research Data
- 2.2. Assumptions

3. EXECUTIVE SUMMARY

- 3.1. Research Highlights

4. MARKET DYNAMICS

- 4.1. Market Drivers
- 4.2. Market Restraints
- 4.3. Porters Five Forces Analysis
 - 4.3.1. Bargaining Power of Suppliers
 - 4.3.2. Bargaining Power of Buyers
 - 4.3.3. Threat of New Entrants
 - 4.3.4. Threat of Substitutes
 - 4.3.5. Competitive Rivalry in the Industry
- 4.4. Industry Value Chain Analysis

5. OPHTHALMIC DRUGS MARKET ANALYSIS, BY INDICATION

- 5.1. Introduction
- 5.2. Dry Eye
- 5.3. Glaucoma
- 5.4. Infection/Inflammation/Allergies
- 5.5. Retinal Problems
- 5.6. Others

6. OPHTHALMIC DRUGS MARKET ANALYSIS, BY PRODUCT TYPE

- 6.1. Introduction
- 6.2. OTC Drug
- 6.3. Prescription Drug

7. OPHTHALMIC DRUGS MARKET ANALYSIS, BY DRUG FORM

- 7.1. Introduction
- 7.2. Liquid
- 7.3. Semi-solid
- 7.4. Solid

8. OPHTHALMIC DRUGS MARKET ANALYSIS, BY DRUG CLASS

- 8.1. Introduction
- 8.2. Anti-Inflammatory
- 8.3. Anesthetic
- 8.4. Anti-Allergy
- 8.5. Others

9. OPHTHALMIC DRUGS MARKET ANALYSIS, BY DELIVERY METHOD

- 9.1. Introduction
- 9.2. Local
 - 9.2.1. Topical
 - 9.2.2. Intravitreous
 - 9.2.3. Sub-conjunctival
 - 9.2.4. Others
- 9.3. Systematic

10. OPHTHALMIC DRUGS MARKET ANALYSIS, BY DISTRIBUTION CHANNEL

- 10.1. Introduction
- 10.2. Online
- 10.3. Offline

11. OPHTHALMIC DRUGS MARKET ANALYSIS, BY GEOGRAPHY

- 11.1. Introduction
- 11.2. North America

- 11.2.1. North America Ophthalmic Drugs Market, By Indication
- 11.2.2. North America Ophthalmic Drugs Market, By Product Type
- 11.2.3. North America Ophthalmic Drugs Market, By Drug Form,2019 to 2025
- 11.2.4. North America Ophthalmic Drugs Market, By Drug Class
- 11.2.5. North America Ophthalmic Drugs Market, By Delivery Method
- 11.2.6. North America Ophthalmic Drugs Market, By Distribution Channel
- 11.2.7. By Country
 - 11.2.7.1. United States
 - 11.2.7.2. Canada
 - 11.2.7.3. Mexico
- 11.3. South America
 - 11.3.1. South America Ophthalmic Drugs Market, By Indication
 - 11.3.2. South America Ophthalmic Drugs Market, By Product Type
 - 11.3.3. South America Ophthalmic Drugs Market, By Drug Form,2019 to 2025
 - 11.3.4. South America Ophthalmic Drugs Market, By Drug Class
 - 11.3.5. South America Ophthalmic Drugs Market, By Delivery Method
 - 11.3.6. South America Ophthalmic Drugs Market, By Distribution Channel
 - 11.3.7. By Country
 - 11.3.7.1. Brazil
 - 11.3.7.2. Argentina
 - 11.3.7.3. Others
- 11.4. Europe
 - 11.4.1. Europe Ophthalmic Drugs Market, By Indication
 - 11.4.2. Europe Ophthalmic Drugs Market, By Product Type
 - 11.4.3. Europe Ophthalmic Drugs Market, By Drug Form,2019 to 2025
 - 11.4.4. Europe Ophthalmic Drugs Market, By Drug Class
 - 11.4.5. Europe Ophthalmic Drugs Market, By Delivery Method
 - 11.4.6. Europe Ophthalmic Drugs Market, By Distribution Channel
 - 11.4.7. By Country
 - 11.4.7.1. UK
 - 11.4.7.2. Germany
 - 11.4.7.3. France
 - 11.4.7.4. Spain
 - 11.4.7.5. Others
- 11.5. Middle East and Africa
 - 11.5.1. Middle East and Africa Ophthalmic Drugs Market, By Indication
 - 11.5.2. Middle East and Africa Ophthalmic Drugs Market, By Product Type
 - 11.5.3. Middle East and Africa Ophthalmic Drugs Market, By Drug Form,2019 to 2025
 - 11.5.4. Middle East and Africa Ophthalmic Drugs Market, By Drug Class

- 11.5.5. Middle East and Africa Ophthalmic Drugs Market, By Delivery Method
- 11.5.6. Middle East and Africa Ophthalmic Drugs Market, By Distribution Channel
- 11.5.7. By Country
 - 11.5.7.1. Saudi Arabia
 - 11.5.7.2. United Arab Emirates
 - 11.5.7.3. Israel
 - 11.5.7.4. Others
- 11.6. Asia Pacific
 - 11.6.1. Asia Pacific Ophthalmic Drugs Market, By Indication
 - 11.6.2. Asia Pacific Ophthalmic Drugs Market, By Product Type
 - 11.6.3. Asia Pacific Ophthalmic Drugs Market, By Drug Form,2019 to 2025
 - 11.6.4. Asia Pacific Ophthalmic Drugs Market, By Drug Class
 - 11.6.5. Asia Pacific Ophthalmic Drugs Market, By Delivery Method
 - 11.6.6. Asia Pacific Ophthalmic Drugs Market, By Distribution Channel
 - 11.6.7. By Country
 - 11.6.7.1. Japan
 - 11.6.7.2. China
 - 11.6.7.3. India
 - 11.6.7.4. Others

12. COMPETITIVE ENVIRONMENT AND ANALYSIS

- 12.1. Major Players and Strategy Analysis
- 12.2. Emerging Players and Market Lucrativeness
- 12.3. Mergers, Acquisitions, Agreements, and Collaborations
- 12.4. Vendor Competitiveness Matrix

13. COMPANY PROFILES

- 13.1. Sun Pharmaceutical Industries, Inc.
- 13.2. Horizon Therapeutics plc
- 13.3. ALLERGAN
- 13.4. Otsuka Pharmaceutical Co., Ltd.
- 13.5. Alcon Inc.
- 13.6. Mundipharma International
- 13.7. F. Hoffmann-La Roche Ltd
- 13.8. Novartis AG
- 13.9. Zydus Cadila
- 13.10. Sentiss Pharma Pvt. Ltd.

- 13.11. Santen Pharmaceutical Co., Ltd
- 13.12. Mallinckrodt Pharmaceuticals
- 13.13. Bausch & Lomb
- 13.14. Regeneron Pharmaceuticals, Inc.
- 13.15. Aerie Pharmaceuticals, Inc

I would like to order

Product name: Ophthalmic Drugs Market - Forecasts from 2020 to 2025

Product link: <https://marketpublishers.com/r/O168F48726F4EN.html>

Price: US\$ 3,160.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O168F48726F4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970